Biomarker For Sensitivity To Mtor Inhibitor Therapy In Kidney Cancer

Document № Publication date Application №
9261498 February 16, 2016 11/886444

The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.